[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 28 of about 28
1. Cossu-Rocca P, Eble JN, Zhang S, Martignoni G, Brunelli M, Cheng L: Acquired cystic disease-associated renal tumors: an immunohistochemical and fluorescence in situ hybridization study. Mod Pathol; 2006 Jun;19(6):780-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acquired cystic disease-associated renal tumors: an immunohistochemical and fluorescence in situ hybridization study.
  • Fluorescence in situ hybridization analysis showed no losses or gains of chromosomes 1, 2, 6, 10, or 17 in one tumor.
  • [MeSH-major] Adenocarcinoma / pathology. In Situ Hybridization, Fluorescence. Kidney Diseases, Cystic / pathology. Kidney Failure, Chronic / pathology. Kidney Neoplasms / pathology
  • [MeSH-minor] Adult. Aneuploidy. Biomarkers, Tumor / metabolism. Chromosomes, Human, 1-3. Chromosomes, Human, Pair 6. DNA, Neoplasm / analysis. Humans. Immunoenzyme Techniques. In Situ Hybridization. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cysts.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16575398.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


2. Tassi E, Wellstein A: The angiogenic switch molecule, secreted FGF-binding protein, an indicator of early stages of pancreatic and colorectal adenocarcinoma. Semin Oncol; 2006 Dec;33(6 Suppl 11):S50-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The angiogenic switch molecule, secreted FGF-binding protein, an indicator of early stages of pancreatic and colorectal adenocarcinoma.
  • We will discuss genetic events underlying the initiation and progression of colorectal and pancreatic adenocarcinoma with a particular focus on the modulation of angiogenesis.
  • Histochemical and in situ hybridization studies with archival samples show that FGF-BP is induced early during the initiation of colorectal and pancreatic adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1999 Apr 1;398(6726):422-6 [10201372.001]
  • [Cites] Oncogene. 1999 May 20;18(20):3098-103 [10340381.001]
  • [Cites] Oncogene. 1999 Apr 29;18(17):2747-54 [10348349.001]
  • [Cites] J Clin Invest. 1999 Aug;104(3):263-9 [10430607.001]
  • [Cites] Nat Med. 1999 Sep;5(9):1071-5 [10470088.001]
  • [Cites] Mutat Res. 1999 Aug;406(2-4):71-7 [10479724.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):739-52 [10487832.001]
  • [Cites] Curr Opin Genet Dev. 1999 Oct;9(5):595-603 [10508699.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Apr;16(2):107-37 [15863029.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Apr;16(2):159-78 [15863032.001]
  • [Cites] Lab Invest. 2005 Jun;85(6):747-55 [15806140.001]
  • [Cites] Crit Rev Oncol Hematol. 2005 Jul;55(1):67-81 [15890525.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2006 Jan;290(1):R105-13 [16352855.001]
  • [Cites] J Biol Chem. 2006 Jan 13;281(2):1137-44 [16257968.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1191-8 [16424058.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4607-12 [9539785.001]
  • [Cites] Bioessays. 1999 Dec;21(12):1021-30 [10580987.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):361-81 [10666364.001]
  • [Cites] Oncogene. 2000 Jan 27;19(4):546-55 [10698524.001]
  • [Cites] Nat Med. 2000 Apr;6(4):389-95 [10742145.001]
  • [Cites] Trends Cell Biol. 2000 Apr;10(4):147-54 [10740269.001]
  • [Cites] Am J Pathol. 2000 Apr;156(4):1363-80 [10751361.001]
  • [Cites] Clin Exp Immunol. 2000 Apr;120(1):59-65 [10759764.001]
  • [Cites] J Clin Gastroenterol. 2000 Apr;30(3):230-3 [10777178.001]
  • [Cites] Am J Pathol. 2000 Jun;156(6):1821-5 [10854204.001]
  • [Cites] Cancer Res. 2000 Jul 15;60(14):3683-8 [10919633.001]
  • [Cites] Nature. 2000 Sep 14;407(6801):249-57 [11001068.001]
  • [Cites] Endocr Relat Cancer. 2000 Sep;7(3):165-97 [11021964.001]
  • [Cites] J Biol Chem. 2001 Mar 30;276(13):10263-71 [11148217.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):579-86 [11342768.001]
  • [Cites] CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36 [11577478.001]
  • [Cites] J Biol Chem. 2001 Oct 26;276(43):40247-53 [11509569.001]
  • [Cites] Oncology (Williston Park). 2001 Oct;15(10):1241-9, 1254; discussion 1254-64 [11702956.001]
  • [Cites] Gut. 2002 Jul;51(1):56-9 [12077092.001]
  • [Cites] Gastroenterology. 2002 Jul;123(1):301-13 [12105858.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 16):15-8 [12516034.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):241-50 [12525515.001]
  • [Cites] Cytokine. 2002 Nov 24;20(4):184-90 [12543084.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1696-705 [12670924.001]
  • [Cites] Pancreas. 2003 May;26(4):344-9 [12717266.001]
  • [Cites] Ann Surg Oncol. 2003 Aug;10(7):722-33 [12900362.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8085-9 [14678957.001]
  • [Cites] Pancreas. 2004 Jan;28(1):25-30 [14707726.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1572-82 [15117979.001]
  • [Cites] Expert Opin Investig Drugs. 2004 Jun;13(6):631-41 [15174949.001]
  • [Cites] Mol Cancer. 2003 Jan 7;2:8 [12556241.001]
  • [Cites] Trends Genet. 2004 Nov;20(11):563-9 [15475116.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] Ann Surg. 1972 Mar;175(3):409-16 [5077799.001]
  • [Cites] Nature. 1987 May 28-Jun 3;327(6120):293-7 [3587348.001]
  • [Cites] Nature. 1987 May 28-Jun 3;327(6120):298-303 [2438556.001]
  • [Cites] Cell. 1988 May 20;53(4):549-54 [2453289.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Science. 1989 Apr 14;244(4901):217-21 [2649981.001]
  • [Cites] Cancer Res. 1989 Sep 1;49(17):4682-9 [2547513.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • [Cites] Science. 1990 Jan 19;247(4940):322-4 [2296722.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] J Biol Chem. 1991 Sep 5;266(25):16778-85 [1885605.001]
  • [Cites] J Biol Chem. 1992 Jun 5;267(16):10931-4 [1375931.001]
  • [Cites] Cancer Res. 1993 Nov 1;53(21):5289-96 [7693336.001]
  • [Cites] Science. 1993 Dec 10;262(5140):1731-4 [8259518.001]
  • [Cites] Science. 1993 Dec 10;262(5140):1734-7 [8259519.001]
  • [Cites] Genomics. 1994 Feb;19(3):525-31 [8188295.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2043-50 [7931472.001]
  • [Cites] Cancer Res. 1994 Nov 15;54(22):5953-8 [7954428.001]
  • [Cites] J Biol Chem. 1994 Nov 11;269(45):28243-8 [7525570.001]
  • [Cites] Virchows Arch. 1994;425(4):357-67 [7820300.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):3046-50 [7708772.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Oct 4;215(1):309-15 [7575607.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] N Engl J Med. 1996 Dec 5;335(23):1727-32 [8929264.001]
  • [Cites] Ann Oncol. 1996 Oct;7(8):843-8 [8922199.001]
  • [Cites] J Pathol. 1996 Dec;180(4):364-70 [9014855.001]
  • [Cites] Nat Med. 1997 Feb;3(2):177-82 [9018236.001]
  • [Cites] Int J Cancer. 1997 May 2;71(3):390-5 [9139874.001]
  • [Cites] Oncogene. 1997 Jun 5;14(22):2671-81 [9178765.001]
  • [Cites] Biochim Biophys Acta. 1997 Jun 7;1332(3):F127-47 [9196022.001]
  • [Cites] Curr Biol. 1997 Jul 1;7(7):R443-6 [9210368.001]
  • [Cites] Oncogene. 1997 Sep 18;15(12):1417-24 [9333017.001]
  • [Cites] Nat Med. 1997 Oct;3(10):1137-40 [9334727.001]
  • [Cites] Gastroenterology. 1998 Apr;114(4):798-807 [9516401.001]
  • [Cites] Pancreas. 1998 Aug;17(2):169-75 [9700949.001]
  • [Cites] Eur J Cancer. 1998 Mar;34(4):518-21 [9713302.001]
  • [Cites] Science. 1998 Sep 4;281(5382):1509-12 [9727977.001]
  • [Cites] Kidney Int Suppl. 1998 Sep;67:S3-6 [9736244.001]
  • [Cites] Br J Cancer. 1998 Sep;78(6):765-70 [9743297.001]
  • [Cites] Oncogene. 1998 Sep 17;17(11 Reviews):1395-413 [9779987.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):139-44 [9874785.001]
  • [Cites] Curr Top Microbiol Immunol. 1999;237:97-132 [9893348.001]
  • [Cites] J Clin Invest. 1999 Jan;103(2):159-65 [9916127.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1998;5(4):383-91 [9931387.001]
  • (PMID = 17178288.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / P01 HL068686; United States / NCI NIH HHS / CA / R01 CA071508; United States / NCI NIH HHS / CA / R01 CA108440; United States / NCI NIH HHS / CA / R01 CA71508
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Intercellular Signaling Peptides and Proteins; 139946-12-6 / FGFBP1 protein, human
  • [Number-of-references] 98
  • [Other-IDs] NLM/ NIHMS15609; NLM/ PMC1781498
  •  go-up   go-down


3. Cossu-Rocca P, Eble JN, Delahunt B, Zhang S, Martignoni G, Brunelli M, Cheng L: Renal mucinous tubular and spindle carcinoma lacks the gains of chromosomes 7 and 17 and losses of chromosome Y that are prevalent in papillary renal cell carcinoma. Mod Pathol; 2006 Apr;19(4):488-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mucinous tubular and spindle cell carcinoma of the kidney is an uncommon, distinctive neoplasm characterized by the proliferation of cuboidal and spindle cells arranged in tubular or sheet-like arrays, typically with a mucinous or myxoid background.
  • The aim of our study is to investigate the pattern of possible gains or losses of chromosomes 7, 17 and Y in 10 mucinous tubular and spindle cell carcinomas with interphase fluorescence in situ hybridization (FISH).
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Papillary / pathology. Carcinoma, Renal Cell / pathology. Chromosome Aberrations. Kidney Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chromosomes, Human, Pair 17 / genetics. Chromosomes, Human, Pair 7 / genetics. Chromosomes, Human, Y / genetics. Diagnosis, Differential. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged


Advertisement
4. Wiesener MS, Münchenhagen P, Gläser M, Sobottka BA, Knaup KX, Jozefowski K, Jürgensen JS, Roigas J, Warnecke C, Gröne HJ, Maxwell PH, Willam C, Eckardt KU: Erythropoietin gene expression in renal carcinoma is considerably more frequent than paraneoplastic polycythemia. Int J Cancer; 2007 Dec 1;121(11):2434-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In situ hybridisation revealed that expression of EPO was in the tumour cells.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Carcinoma, Renal Cell / metabolism. Erythropoietin / metabolism. Kidney Neoplasms / metabolism. Paraneoplastic Syndromes / epidemiology. Polycythemia / epidemiology
  • [MeSH-minor] Basic Helix-Loop-Helix Transcription Factors / metabolism. Cell Line, Tumor. Gene Expression Regulation, Neoplastic. Germany / epidemiology. Humans. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Immunoblotting. In Situ Hybridization. Prevalence. RNA, Messenger / metabolism. Ribonucleases / metabolism. Signal Transduction. Tumor Cells, Cultured. Up-Regulation

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17640059.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / RNA, Messenger; 0 / endothelial PAS domain-containing protein 1; 11096-26-7 / Erythropoietin; EC 3.1.- / Ribonucleases
  •  go-up   go-down


5. Okoń K, Klimkowska A, Pawelec A, Dobrowolski Z, Kohla Z, Stachura J: Immunophenotype and cytogenetics of mucinous tubular and spindle cell carcinoma of the kidney. Pol J Pathol; 2007;58(4):227-33
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotype and cytogenetics of mucinous tubular and spindle cell carcinoma of the kidney.
  • Mucinous tubular and spindle cell carcinoma (MTSCC) of the kidney is a rare, recently described entity.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Carcinoma / metabolism. Carcinoma / pathology. Kidney Neoplasms / metabolism. Kidney Neoplasms / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Cytogenetics. Female. Humans. Immunohistochemistry. Immunophenotyping. In Situ Hybridization, Fluorescence. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Pol J Pathol. 2008;59(1):14
  • (PMID = 18459456.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


6. Allory Y, Matsuoka Y, Bazille C, Christensen EI, Ronco P, Debiec H: The L1 cell adhesion molecule is induced in renal cancer cells and correlates with metastasis in clear cell carcinomas. Clin Cancer Res; 2005 Feb 1;11(3):1190-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objectives of the study were to provide a comprehensive description of L1 distribution in human kidney and to establish the prognostic relevance of L1 expression in renal cell carcinomas (RCC).
  • EXPERIMENTAL DESIGN: Using two antibodies to the extracellular part and the cytoplasmic domain, respectively, we first compared L1 expression in normal kidney and renal tumors of diverse histopathologic origin, then we studied L1 expression together with tumor stage, grade, molecular prognostic biomarkers, and metastatic behavior.
  • RESULTS: In normal kidney, L1 immunoreactive with both antibodies was expressed in all epithelial cells originating from the ureteric bud except for intercalated cells.
  • In renal tumors, L1 was mainly detected in those originating from cells that do not express L1 in the normal kidney [i.e., 33 of 72 clear cell RCC (ccRCC) and 25 of 88 papillary RCC (papRCC)].
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Neural Cell Adhesion Molecule L1 / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cyclin D1 / analysis. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. In Situ Hybridization. Ki-67 Antigen / analysis. Kidney / chemistry. Kidney / metabolism. Male. Middle Aged. Neoplasm Metastasis. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Survival Analysis

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15709188.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Neural Cell Adhesion Molecule L1; 0 / RNA, Messenger; 136601-57-5 / Cyclin D1
  •  go-up   go-down


7. Brandal P, Lie AK, Bassarova A, Svindland A, Risberg B, Danielsen H, Heim S: Genomic aberrations in mucinous tubular and spindle cell renal cell carcinomas. Mod Pathol; 2006 Feb;19(2):186-94
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mucinous tubular and spindle cell carcinoma of the kidney is a new diagnostic entity.
  • Interphase fluorescence in situ hybridization analyses with centromere-specific probes for chromosomes 1, 3, 4, 6, 7, 9, 10, 17, 18, 20, and X showed that the two hypodiploid tumors had disomic and monosomic chromosome populations, whereas the karyotyped, near-triploid tumor was dominated by trisomic chromosome populations.
  • We conclude that multiple numerical chromosome aberrations may be a feature of mucinous tubular and spindle cell carcinomas of the kidney, but beyond that no clear-cut karyotypic aberration pattern is so far discernible.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma / pathology. Carcinoma, Renal Cell / pathology. Chromosome Aberrations. Kidney Neoplasms / pathology
  • [MeSH-minor] Adult. Aged, 80 and over. DNA, Neoplasm / analysis. DNA, Neoplasm / genetics. Female. Genome, Human. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Karyotyping. Keratin-7. Keratins / analysis. Male. Middle Aged. Mucin-1 / analysis. Nucleic Acid Hybridization / methods. Vimentin / analysis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258504.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / KRT7 protein, human; 0 / Keratin-7; 0 / Mucin-1; 0 / Vimentin; 68238-35-7 / Keratins
  •  go-up   go-down


8. Liu W, Liu Y, Zhu J, Wright E, Ding I, Rodgers GP: Reduced hGC-1 protein expression is associated with malignant progression of colon carcinoma. Clin Cancer Res; 2008 Feb 15;14(4):1041-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: The expression of hGC-1 in colon adenocarcinoma tissues was examined by dot-blot analysis, in situ hybridization, and immunohistochemistry.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Colonic Neoplasms / metabolism. Colonic Neoplasms / pathology. Granulocyte Colony-Stimulating Factor / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Cell Adhesion / physiology. Cell Line, Tumor. Cell Movement / physiology. DNA Methylation. DNA Mutational Analysis. Disease Progression. Female. Gene Expression. HT29 Cells. Humans. Immunoblotting. Immunohistochemistry. In Situ Hybridization. Kaplan-Meier Estimate. Male. Microscopy, Confocal. Middle Aged. Promoter Regions, Genetic. RNA, Messenger / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18281536.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


9. Brunelli M, Gobbo S, Cossu-Rocca P, Cheng L, Ficarra V, Novara G, Menestrina F, Chilosi M, Martignoni G: Fluorescent cytogenetics of renal cell neoplasms. Pathologica; 2008 Dec;100(6):454-60
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The genetics of these tumours may aid in correct diagnosis and accurate assessment of prognosis.
  • Fluorescence in situ hybridization (FISH) on formalin-fixed, paraffin-embedded tissue is an increasingly useful technique in the detection of many diagnostic chromosomal abnormalities, among which chromosomes 1, 2, 3p, 6, 7, 10, 17 and Y are the most common.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. In Situ Hybridization, Fluorescence. Kidney Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / pathology. Adenoma / diagnosis. Adenoma / genetics. Adenoma / pathology. Adenoma, Oxyphilic / diagnosis. Adenoma, Oxyphilic / genetics. Adenoma, Oxyphilic / pathology. Adult. Aneuploidy. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / genetics. Carcinoma, Papillary / pathology. Child. Chromosome Aberrations. Chromosomes, Human / ultrastructure. Chromosomes, Human, X / ultrastructure. Humans. Kidney Failure, Chronic / complications. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19475886.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 54
  •  go-up   go-down


10. Argani P, Netto GJ, Parwani AV: Papillary renal cell carcinoma with low-grade spindle cell foci: a mimic of mucinous tubular and spindle cell carcinoma. Am J Surg Pathol; 2008 Sep;32(9):1353-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The solid variant of papillary renal cell carcinoma (PRCC) is distinguishable genetically from mucinous tubular and spindle cell carcinoma (MTSC) of the kidney by the presence of trisomy for chromosomes 7 and 17; however, at the morphologic and immunohistochemical levels, these neoplasms overlap significantly.
  • All 5 cases showed trisomy of chromosome 7, and 3 of 5 showed trisomy of chromosome 17 by fluorescence in situ hybridization, supporting classification as PRCC.
  • Before a diagnosis of metastatic MTSC or MTSC with unusual morphology is rendered, the possibility of PRCC with low-grade spindle cell foci should be considered.
  • Fluorescence in situ hybridization analysis effectively separates these morphologically very similar yet genetically distinctive entities.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma / pathology. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Chromosomes, Human, Pair 17 / genetics. Chromosomes, Human, Pair 7 / genetics. Diagnosis, Differential. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Trisomy


11. Chyhrai A, Sanjmyatav J, Gajda M, Reichelt O, Wunderlich H, Steiner T, Tanović E, Junker K: Multi-colour FISH on preoperative renal tumour biopsies to confirm the diagnosis of uncertain renal masses. World J Urol; 2010 Jun;28(3):269-74
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multi-colour FISH on preoperative renal tumour biopsies to confirm the diagnosis of uncertain renal masses.
  • PURPOSE: In some cases with uncertain renal tumour lesions, it would be helpful to perform biopsies for the preoperative differential diagnosis.
  • In our study, we evaluated the benefit of multi-colour interphase fluorescence in situ hybridization (M-FISH) on fine-needle core biopsies in uncertain renal masses.
  • RESULTS: 16 were classified as renal malignancies: 14 (56%) clear cell renal cell carcinomas (RCCs), 1 papillary RCCs (4%), and 1 "adenocarcinoma" (4%).
  • The M-FISH represents a new highly sensitive and specific method to confirm histopathological classification in less than 24 h which can be used in routine laboratory diagnosis.
  • [MeSH-major] Biopsy, Fine-Needle / methods. In Situ Hybridization, Fluorescence. Kidney Neoplasms / pathology. Kidney Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / diagnostic imaging. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Aged. Carcinoma, Renal Cell / diagnostic imaging. Carcinoma, Renal Cell / pathology. Carcinoma, Renal Cell / surgery. Cohort Studies. Diagnosis, Differential. Female. Humans. Leiomyoma / diagnostic imaging. Leiomyoma / pathology. Leiomyoma / surgery. Male. Middle Aged. Neoplasm Staging. Nephrectomy / methods. Preoperative Care / methods. Prospective Studies. Sensitivity and Specificity. Ultrasonography, Interventional / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2008 Oct;180(4):1257-61; discussion 1261 [18707712.001]
  • [Cites] Orv Hetil. 1999 Oct 10;140(41):2325 [10603746.001]
  • [Cites] Urologe A. 1999 Sep;38(5):425-32 [10501700.001]
  • [Cites] J Pathol. 1997 Oct;183(2):131-3 [9390023.001]
  • [Cites] Eur Urol. 2009 Feb;55(2):359-67 [18849108.001]
  • [Cites] Recent Results Cancer Res. 2003;162:169-75 [12790331.001]
  • [Cites] Prog Urol. 2000 Dec;10 (6):1145-51 [11217550.001]
  • [Cites] J Urol. 1999 May;161(5):1470-4 [10210375.001]
  • [Cites] Clin Radiol. 2004 Mar;59(3):262-7 [15037139.001]
  • [Cites] Semin Urol Oncol. 1995 Nov;13(4):254-61 [8595548.001]
  • [Cites] J Urol. 2004 May;171(5):1802-5 [15076280.001]
  • [Cites] Genes Chromosomes Cancer. 1997 May;19(1):29-35 [9135992.001]
  • [Cites] J Urol. 2008 Apr;179(4):1227-33; discussion 1233-4 [18280512.001]
  • [Cites] BJU Int. 2007 May;99(5):1002-6 [17437434.001]
  • [Cites] J Urol. 2003 Dec;170(6 Pt 1):2217-20 [14634382.001]
  • [Cites] Am J Surg Pathol. 2003 May;27(5):612-24 [12717246.001]
  • [Cites] Eur Urol. 2006 May;49(5):798-805 [16442207.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Apr 15;158(2):110-8 [15796957.001]
  • [Cites] Urology. 2000 Mar;55(3):348-52 [10699608.001]
  • [Cites] Am J Surg Pathol. 1997 Jun;21(6):621-35 [9199639.001]
  • [Cites] Diagn Cytopathol. 2000 Jan;22(1):3-6 [10613963.001]
  • [Cites] Acta Cytol. 1997 Jul-Aug;41(4):987-94 [9250289.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Jul;22(3):171-8 [9624528.001]
  • [Cites] Eur Urol. 2007 Nov;52(5):1421-6 [17306920.001]
  • [Cites] J Urol. 2005 Jul;174(1):44-6 [15947574.001]
  • [Cites] J Urol. 2001 Sep;166(3):1088-92 [11490304.001]
  • [Cites] Radiology. 2000 Aug;216(2):506-10 [10924578.001]
  • [Cites] J Urol. 2006 Nov;176(5):1957-62 [17070218.001]
  • [Cites] J Urol. 2005 Aug;174(2):731-5 [16006966.001]
  • [Cites] Histopathology. 2004 Jun;44(6):542-6 [15186268.001]
  • [Cites] Arch Ital Urol Androl. 2009 Jun;81(2):107-12 [19760866.001]
  • (PMID = 20390284.001).
  • [ISSN] 1433-8726
  • [Journal-full-title] World journal of urology
  • [ISO-abbreviation] World J Urol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


12. Hwa JS, Kim HJ, Goo BM, Park HJ, Kim CW, Chung KH, Park HC, Chang SH, Kim YW, Kim DR, Cho GJ, Choi WS, Kang KR: The expression of ketohexokinase is diminished in human clear cell type of renal cell carcinoma. Proteomics; 2006 Feb;6(3):1077-84
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For identification and targeting of tumor-associated marker proteins, the proteome of clear cell type of renal cell carcinoma (RCC) and normal kidney tissues was analyzed by 2-DE.
  • We found a decreased amount of ketohexokinase mRNA in RCC compared to that observed in the normal kidney tissues by Northern blot.
  • The activity of ketohexokinase in 20 clear cell RCC specimens and the 20 corresponding normal kidneys was investigated, and its activity was shown to be approximately 1.4-fold lower in the RCC specimens than in the normal kidney.
  • In addition, using in situ hybridization, it was revealed that ketohexokinase in the normal kidney tissue was confined to the proximal tubular epithelial cells, while the expression of ketohexokinase in RCC tissues was extremely low.
  • [MeSH-major] Adenocarcinoma, Clear Cell / enzymology. Biomarkers, Tumor / metabolism. Carcinoma, Renal Cell / enzymology. Fructokinases / metabolism. Kidney Neoplasms / enzymology. Proteome / metabolism
  • [MeSH-minor] Blotting, Northern. Gene Expression Regulation, Neoplastic. Humans. Kidney / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Clear Cell Renal Cell Carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16372272.001).
  • [ISSN] 1615-9853
  • [Journal-full-title] Proteomics
  • [ISO-abbreviation] Proteomics
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proteome; 0 / RNA, Messenger; EC 2.7.1.- / Fructokinases; EC 2.7.1.3 / ketohexokinase
  •  go-up   go-down


13. Shannon BA, Cohen RJ, Segal A, Baker EG, Murch AR: Clear cell renal cell carcinoma with smooth muscle stroma. Hum Pathol; 2009 Mar;40(3):425-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fluorescence in situ hybridization analysis of chromosome 3 showed loss of the entire chromosome in 2 cases and loss of 3p in the third case.
  • Extensive tissue sampling and immunostaining are recommended to distinguish cases with an extensive smooth muscle component from morphologically similar but benign lesions including angiomyolipoma, leiomyoma, or mixed epithelial and stromal tumor of the kidney.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Kidney Neoplasms / pathology. Muscle, Smooth / pathology. Stromal Cells / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Chromosome Deletion. Chromosomes, Human, Pair 3. Disease-Free Survival. Female. Humans. In Situ Hybridization, Fluorescence. Male. Microscopy, Electron, Transmission. Middle Aged. Nephrectomy


14. Canchola AJ, Horn-Ross PL, Purdie DM: Risk of second primary malignancies in women with papillary thyroid cancer. Am J Epidemiol; 2006 Mar 15;163(6):521-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Second malignancies in women diagnosed with thyroid cancer are of concern given the young average age at diagnosis and excellent survival.
  • Follow-up was calculated from 2 months until the diagnosis of a second primary cancer, death, loss to follow-up, or December 31, 1999, whichever occurred first.
  • An excess of in situ breast cancer (SIR = 1.6, 95% CI: 1.0, 2.4), kidney cancer (SIR = 3.9, 95% CI: 2.2, 6.3), and melanoma (SIR = 2.1, 95% CI: 1.3, 3.2) limited to the first 5 years after diagnosis was observed.
  • Women with papillary thyroid cancer are at increased risk of in situ, but not invasive, breast cancer, kidney cancer, and melanoma.
  • [MeSH-major] Adenocarcinoma, Papillary / epidemiology. Breast Neoplasms / epidemiology. Kidney Neoplasms / epidemiology. Melanoma / epidemiology. Neoplasms, Second Primary / epidemiology. Thyroid Neoplasms / epidemiology


15. Tao Q, Fujimoto J, Men T, Ye X, Deng J, Lacroix L, Clifford JL, Mao L, Van Pelt CS, Lee JJ, Lotan D, Lotan R: Identification of the retinoic acid-inducible Gprc5a as a new lung tumor suppressor gene. J Natl Cancer Inst; 2007 Nov 21;99(22):1668-82
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human embryonic kidney, human non-small-cell lung cancer, and mouse lung adenocarcinoma cells were transfected with a GPRC5A expression vector or a control vector, and colony formation in semisolid medium was assayed.
  • The mean GPRC5A mRNA level in adenocarcinoma (n = 139), squamous cell carcinoma (n = 21), small-cell lung cancer (n = 6), and carcinoid (n = 20) tissues was 46.2% (P = .014), 7.5% (P<.001), 5.3% (P<.001), and 1.8% (P<.001), respectively, that in normal lung tissues (n = 17) GPRC5A transfection suppressed colony formation in semisolid medium of immortalized human embryonic kidney, human non-small-cell lung cancer, and mouse lung adenocarcinoma cells by 91%, 91%, and 68%, respectively, compared with vector controls (all P<.001).
  • [MeSH-major] Adenocarcinoma / chemistry. Genes, Tumor Suppressor. Lung / chemistry. Lung Neoplasms / chemistry. Neoplastic Stem Cells / chemistry. Receptors, G-Protein-Coupled / genetics. Respiratory Mucosa / pathology
  • [MeSH-minor] Animals. Blotting, Northern. Carcinoma, Non-Small-Cell Lung / chemistry. Carcinoma, Small Cell / chemistry. Cell Line, Tumor. Cell Transformation, Neoplastic. Disease Models, Animal. Embryonic Stem Cells. Fluorescent Antibody Technique. Gene Expression Regulation, Neoplastic. Genes, ras. Genetic Predisposition to Disease. Homozygote. Humans. Immunoblotting. Immunohistochemistry. In Situ Hybridization. Mice. Mice, Knockout. Mutation. Neoplasm Proteins / genetics. Phenotype. Protein Array Analysis. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Transfection. Tumor Stem Cell Assay


16. Godoy A, Ulloa V, Rodríguez F, Reinicke K, Yañez AJ, García Mde L, Medina RA, Carrasco M, Barberis S, Castro T, Martínez F, Koch X, Vera JC, Poblete MT, Figueroa CD, Peruzzo B, Pérez F, Nualart F: Differential subcellular distribution of glucose transporters GLUT1-6 and GLUT9 in human cancer: ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues. J Cell Physiol; 2006 Jun;207(3):614-27
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • GLUT6 was principally detected in testis germinal cells and GLUT9 was localized in kidney, liver, heart, and adrenal.
  • GLUT5 was detected in 27% of breast and colon adenocarcinoma, liver carcinoma, lymphomas, and testis seminoma samples.
  • In situ RT-PCR and ultrastructural immunohistochemistry confirmed GLUT5 expression in breast cancer.
  • [MeSH-minor] Animals. Biopsy. Gene Expression Regulation, Neoplastic. Health. Humans. Immunohistochemistry. In Situ Hybridization. Mice. Microscopy, Immunoelectron. Organ Specificity. Rats. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16523487.001).
  • [ISSN] 0021-9541
  • [Journal-full-title] Journal of cellular physiology
  • [ISO-abbreviation] J. Cell. Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucose Transport Proteins, Facilitative
  •  go-up   go-down


17. Sterlacci W, Verdorfer I, Gabriel M, Mikuz G: Thyroid follicular carcinoma-like renal tumor: a case report with morphologic, immunophenotypic, cytogenetic, and scintigraphic studies. Virchows Arch; 2008 Jan;452(1):91-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chromosomal losses of 1, 3, 7, 9p21, 12, 17, and X were detected by fluorescence in situ hybridization.
  • Scintigraphs showed an inconspicuous thyroid gland and no extrathyroidal pathological accumulations, making metastatic spread to the kidney highly unlikely.
  • [MeSH-major] Adenocarcinoma, Follicular / secondary. Kidney Neoplasms / secondary. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Chromosome Deletion. Cytogenetics. Diagnosis, Differential. Disease-Free Survival. Female. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Nephrectomy. Radionuclide Imaging. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Virchows Arch. 2009 Jun;454(6):717-8 [19449026.001]
  • [ErratumIn] Virchows Arch. 2008 Apr;452(4):471. William, Sterlacci [corrected to Sterlacci, William]; Irmgard, Verdorfer [corrected to Verdorfer, Irmgard]; Michael, Gabriel [corrected to Gabriel, Michael]; Gregor, Mikuz [corrected to Mikuz, Gregor]
  • [Cites] Ann Pathol. 2004 Oct;24(5):395-406 [15738865.001]
  • [Cites] Obstet Gynecol. 1963 May;21:567-76 [13949036.001]
  • [Cites] Cancer. 1983 Jan 15;51(2):337-43 [6821820.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2002 Dec;10(4):332-8 [12613443.001]
  • [Cites] Chin Med J (Engl). 2004 Oct;117(10):1588-9 [15498392.001]
  • [Cites] Arch Pathol Lab Med. 2005 Apr;129(4):487-91 [15794671.001]
  • [Cites] Hum Pathol. 2000 Sep;31(9):1139-45 [11014583.001]
  • [Cites] Acta Obstet Gynecol Scand. 1964;42:399-424 [14131800.001]
  • [Cites] Cancer. 1997 Mar 1;79(5):975-81 [9041160.001]
  • [Cites] Pathol Annu. 1976;11:403-13 [1004942.001]
  • [Cites] Cancer. 1987 Feb 1;59(3):471-6 [3539312.001]
  • [Cites] Am J Pathol. 1994 Aug;145(2):356-64 [7519827.001]
  • [Cites] World J Surg Oncol. 2006 May 03;4:24 [16672060.001]
  • [Cites] Gynecol Obstet Invest. 1997;43(1):68-72 [9015705.001]
  • [Cites] Cancer Genet Cytogenet. 1999 May;111(1):61-70 [10326593.001]
  • [Cites] Int J Gynecol Pathol. 1993 Oct;12(4):333-43 [8253550.001]
  • [Cites] Adv Cancer Res. 1993;62:89-124 [8109322.001]
  • [Cites] J Laryngol Otol. 1993 Dec;107(12):1174-6 [8289014.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Apr 15;158(2):110-8 [15796957.001]
  • [Cites] Histopathology. 1988 Jul;13(1):43-54 [3061922.001]
  • [Cites] Semin Oncol. 2000 Apr;27(2):124-37 [10768592.001]
  • [Cites] Zhonghua Bing Li Xue Za Zhi. 2004 Apr;33(2):140-2 [15132851.001]
  • [Cites] J Nucl Med. 1999 Jun;40(6):986-92 [10452315.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Dec;86(12):5686-90 [11739420.001]
  • [Cites] Am J Surg Pathol. 2006 Mar;30(3):411-5 [16538064.001]
  • [Cites] Arch Pathol Lab Med. 1978 Apr;102(4):180-4 [580711.001]
  • [Cites] Cancer Genet Cytogenet. 2007 May;175(1):1-7 [17498551.001]
  • [Cites] Ceylon Med J. 1993 Sep;38(3):113-6 [7828228.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • (PMID = 17704942.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


18. Kim J, Kim MA, Jee CD, Jung EJ, Kim WH: Reduced expression and homozygous deletion of annexin A10 in gastric carcinoma. Int J Cancer; 2009 Oct 15;125(8):1842-50
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Apoptosis. Blotting, Western. Case-Control Studies. Cell Movement. Cell Proliferation. Cells, Cultured. Chromosome Mapping. Chromosomes, Human, Pair 4 / genetics. Colony-Forming Units Assay. Comparative Genomic Hybridization. Female. Gene Expression Profiling. Humans. Immunoblotting. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Kidney / embryology. Kidney / metabolism. Kidney / pathology. Lymphatic Metastasis. Male. Mutation / genetics. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Small Interfering / pharmacology. Reverse Transcriptase Polymerase Chain Reaction. Stomach / metabolism. Stomach / pathology. Tissue Array Analysis. Tumor Cells, Cultured. Wound Healing

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19582876.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ANXA10 protein, human; 0 / Annexins; 0 / RNA, Messenger; 0 / RNA, Small Interfering
  •  go-up   go-down


19. Pankhurst T, Howie AJ, Adu D, Wallace DM, Lipkin GW: Incidental neoplasms in renal biopsies. Nephrol Dial Transplant; 2006 Jan;21(1):64-9
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twenty-two neoplasms were papillary, two were clear cell renal carcinomas and one was in situ carcinoma in a collecting duct.
  • [MeSH-major] Incidental Findings. Kidney Neoplasms / epidemiology. Kidney Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Papillary / epidemiology. Adenocarcinoma, Papillary / pathology. Adult. Age Distribution. Aged. Aged, 80 and over. Biopsy, Needle. Carcinoma, Renal Cell / epidemiology. Carcinoma, Renal Cell / pathology. Female. Great Britain / epidemiology. Humans. Immunohistochemistry. Incidence. Magnetic Resonance Imaging. Male. Middle Aged. Retrospective Studies. Risk Assessment. Sex Distribution. Ultrasonography, Doppler

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16204290.001).
  • [ISSN] 0931-0509
  • [Journal-full-title] Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • [ISO-abbreviation] Nephrol. Dial. Transplant.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


20. Argani P, Aulmann S, Karanjawala Z, Fraser RB, Ladanyi M, Rodriguez MM: Melanotic Xp11 translocation renal cancers: a distinctive neoplasm with overlapping features of PEComa, carcinoma, and melanoma. Am J Surg Pathol; 2009 Apr;33(4):609-19
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both neoplasms demonstrated nuclear labeling for TFE3 protein by immunohistochemistry, and the presence of TFE3 gene fusions was confirmed by TFE3 fluorescence in situ hybridization analysis.
  • [MeSH-major] Adenocarcinoma / secondary. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, X / genetics. Kidney Neoplasms / pathology. Melanoma / secondary. Perivascular Epithelioid Cell Neoplasms / secondary. Translocation, Genetic
  • [MeSH-minor] Basic Helix-Loop-Helix Leucine Zipper Transcription Factors / genetics. Basic Helix-Loop-Helix Leucine Zipper Transcription Factors / metabolism. Biomarkers, Tumor / metabolism. Child. Epithelioid Cells / metabolism. Epithelioid Cells / pathology. Fatal Outcome. Female. Gene Fusion. Humans. In Situ Hybridization, Fluorescence. Male. Melanins / metabolism. Neoplasms, Multiple Primary

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19065101.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; 0 / Biomarkers, Tumor; 0 / Melanins; 0 / TFE3 protein, human
  •  go-up   go-down


21. Kuroda N, Hes O, Michal M, Nemcova J, Gal V, Yamaguchi T, Kawada T, Imamura Y, Hayashi Y, Lee GH: Mucinous tubular and spindle cell carcinoma with Fuhrman nuclear grade 3: a histological, immunohistochemical, ultrastructural and FISH study. Histol Histopathol; 2008 12;23(12):1517-23
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mucinous tubular and spindle cell carcinoma (MTSCC) of the kidney generally shows low nuclear grade.
  • FISH analysis may be helpful in establishing the diagnosis of this entity.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology
  • [MeSH-minor] Fatal Outcome. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Microscopy, Electron, Transmission. Middle Aged. Racemases and Epimerases / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18830937.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


22. Ljuslinder I, Golovleva I, Palmqvist R, Oberg A, Stenling R, Jonsson Y, Hedman H, Henriksson R, Malmer B: LRIG1 expression in colorectal cancer. Acta Oncol; 2007;46(8):1118-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • LRIG1 is expressed in all tissues and organs analysed to date, including breast, brain, skin, kidney, spleen and colon.
  • FISH (fluoroscence in situ hybridisAtion) analysis showed increased LRIG1 copy number in one of nine tumours.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Colorectal Neoplasms / genetics. Colorectal Neoplasms / metabolism. Membrane Glycoproteins / genetics. Membrane Glycoproteins / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17851870.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / LRIG1 protein, human; 0 / Membrane Glycoproteins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


23. Chang YS, Adnane J, Trail PA, Levy J, Henderson A, Xue D, Bortolon E, Ichetovkin M, Chen C, McNabola A, Wilkie D, Carter CA, Taylor IC, Lynch M, Wilhelm S: Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol; 2007 Apr;59(5):561-74
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / pathology. Angiogenesis Inhibitors / therapeutic use. Anoxia / chemically induced. Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Kidney Neoplasms / drug therapy. Kidney Neoplasms / pathology. Pyridines / therapeutic use
  • [MeSH-minor] Actins / metabolism. Animals. Antigens, CD31 / immunology. Capillaries / pathology. Cell Line, Tumor. Female. Humans. Immunohistochemistry. In Situ Nick-End Labeling. Mice. Mice, Nude. Niacinamide / analogs & derivatives. Phenylurea Compounds. Regional Blood Flow / drug effects. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17160391.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Actins; 0 / Angiogenesis Inhibitors; 0 / Antigens, CD31; 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 0 / Vascular Endothelial Growth Factor A; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


24. Gupta K, Nada R, Das A, Kumar MS: Membranoproliferative glomerulonephritis in a carcinoma with unknown primary: an autopsy study. Indian J Pathol Microbiol; 2008 Apr-Jun;51(2):230-3
Genetic Alliance. consumer health - Glomerulonephritis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kidney disease frequently complicates malignancy and its treatment.
  • The mechanism by which malignancy induces disease remains unproved, but may involve deposition of tumor antigen in the subepithelial space with in situ immune complex formation and subsequent complement activation.
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / pathology. Adult. Humans. Male. Splenic Neoplasms / complications. Splenic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18603690.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


25. Sun Q, Weber CR, Sohail A, Bernardo MM, Toth M, Zhao H, Turner JR, Fridman R: MMP25 (MT6-MMP) is highly expressed in human colon cancer, promotes tumor growth, and exhibits unique biochemical properties. J Biol Chem; 2007 Jul 27;282(30):21998-2010
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we found a marked increase in MT6-MMP expression within in situ dysplasia and invasive cancer in 61 samples of human colon cancer.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Res. 1999 Dec;9(4):291-303 [10628838.001]
  • [Cites] J Biol Chem. 2000 Jan 28;275(4):2661-8 [10644727.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):877-82 [10706098.001]
  • [Cites] J Biol Chem. 2000 Apr 21;275(16):12080-9 [10766841.001]
  • [Cites] J Biol Chem. 2000 May 12;275(19):14046-55 [10799478.001]
  • [Cites] FEBS Lett. 2000 Sep 1;480(2-3):142-6 [11034316.001]
  • [Cites] FEBS Lett. 2001 Feb 23;491(1-2):137-42 [11226436.001]
  • [Cites] J Biol Chem. 2001 Jun 15;276(24):21960-8 [11282999.001]
  • [Cites] J Biol Chem. 2001 Jul 13;276(28):25705-14 [11335709.001]
  • [Cites] EMBO J. 2001 Sep 3;20(17):4782-93 [11532942.001]
  • [Cites] J Biol Chem. 2002 Mar 29;277(13):11201-7 [11790786.001]
  • [Cites] Cancer Res. 2002 Apr 15;62(8):2227-31 [11956073.001]
  • [Cites] Semin Cancer Biol. 2002 Apr;12(2):131-8 [12027585.001]
  • [Cites] J Biol Chem. 2002 Jul 19;277(29):26340-50 [12004057.001]
  • [Cites] J Biol Chem. 2002 Nov 8;277(45):43399-409 [12202484.001]
  • [Cites] Mol Cancer Res. 2003 Mar;1(5):333-45 [12651907.001]
  • [Cites] Curr Top Dev Biol. 2003;54:1-74 [12696745.001]
  • [Cites] J Biol Chem. 2003 Sep 19;278(38):36350-7 [12860995.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6758-62 [14583471.001]
  • [Cites] Brain. 2003 Dec;126(Pt 12):2738-49 [14506071.001]
  • [Cites] Mol Biotechnol. 2003 Nov;25(3):241-66 [14668538.001]
  • [Cites] J Biol Chem. 2004 Mar 5;279(10):8592-601 [14681236.001]
  • [Cites] Exp Cell Res. 2004 Jun 10;296(2):145-50 [15149845.001]
  • [Cites] Mol Cell Biol. 1987 Jul;7(7):2538-44 [3112559.001]
  • [Cites] J Biol Chem. 1992 Aug 5;267(22):15398-405 [1322396.001]
  • [Cites] Kidney Int. 1993 Jan;43(1):158-62 [8433555.001]
  • [Cites] J Biol Chem. 1995 Mar 10;270(10):5331-8 [7890645.001]
  • [Cites] Methods Enzymol. 1995;248:18-34 [7674921.001]
  • [Cites] J Biol Chem. 1997 Nov 21;272(47):29975-83 [9368077.001]
  • [Cites] Biochem J. 1998 Sep 1;334 ( Pt 2):325-33 [9716490.001]
  • [Cites] Br J Cancer. 2005 Jun 20;92(12):2171-80 [15928670.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2005 Jul;46(7):2388-95 [15980226.001]
  • [Cites] Cardiovasc Res. 2006 Feb 15;69(3):562-73 [16405877.001]
  • [Cites] Br J Cancer. 2006 Feb 27;94(4):569-77 [16465195.001]
  • [Cites] J Biol Chem. 2006 Apr 14;281(15):10337-46 [16469749.001]
  • [Cites] Cancer Metastasis Rev. 2006 Mar;25(1):9-34 [16680569.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5165-72 [16707440.001]
  • [Cites] Genes Dev. 2006 Oct 1;20(19):2673-86 [16983145.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Nov 17;350(2):377-84 [17007816.001]
  • (PMID = 17513868.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R56 DK094954; United States / NIDDK NIH HHS / DK / P01 DK067887; United States / NIDDK NIH HHS / DK / R01 DK68271; United States / NCI NIH HHS / CA / CA100475-04; United States / NIDDK NIH HHS / DK / DK068271-02; United States / NCI NIH HHS / CA / P30 CA14599; United States / NCI NIH HHS / CA / P30 CA014599; United States / NCI NIH HHS / CA / CA100475; United States / NCI NIH HHS / CA / R01 CA061986; United States / NIDDK NIH HHS / DK / DK061931-06; United States / NIDDK NIH HHS / DK / R01 DK061931-06; United States / NIDDK NIH HHS / DK / R01 DK61931; United States / NIDDK NIH HHS / DK / R01 DK061931; United States / NIDDK NIH HHS / DK / R01 DK068271; United States / NCI NIH HHS / CA / R01 CA100475-04; United States / NCI NIH HHS / CA / CA061986-12; United States / NCI NIH HHS / CA / R01 CA61986-11; United States / NCI NIH HHS / CA / R01 CA100475; United States / NIDDK NIH HHS / DK / R01 DK068271-02; United States / NCI NIH HHS / CA / R01 CA061986-12
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GPI-Linked Proteins; 0 / Glycosylphosphatidylinositols; 0 / Neoplasm Proteins; 0 / Tissue Inhibitor of Metalloproteinase-1; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; EC 3.4.24.- / Matrix Metalloproteinases, Membrane-Associated; EC 3.4.24.- / matrix metalloproteinase 25
  • [Other-IDs] NLM/ NIHMS27651; NLM/ PMC1978545
  •  go-up   go-down


26. Bennett VS, Bailey DM: Cholangiocarcinoma presenting as a solitary epididymal metastasis: a case report and review of the literature. Diagn Pathol; 2007;2:33

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Other primary carcinomas that have been demonstrated to metastasize to the paratesticular region include those originating in the stomach, kidney, ileum, and colon.
  • Computed tomography of the abdomen demonstrated an obstructive stricture of the extra-hepatic bile ducts, in keeping with a cholangiocarcinoma, through which a metal stent was endoscopically inserted for symptomatic relief.Subsequent right radical orchidectomy yielded a diffusely infiltrative adenocarcinoma obliterating the epididymis, extending into the rete testis, vas deferens and spermatic cord and showing widespread vascular and perineural invasion.
  • Residual epididymal, rete, and testicular tubules showed no in situ neoplasia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Urol. 1983;9(1):56-9 [6822245.001]
  • [Cites] Jpn J Clin Oncol. 1994 Dec;24(6):340-4 [7830340.001]
  • [Cites] Br J Surg. 1997 Feb;84(2):198-9 [9052433.001]
  • [Cites] Int J Urol. 1998 Jan;5(1):106-7 [9535613.001]
  • [Cites] Histopathology. 2000 Oct;37(4):323-31 [11012739.001]
  • [Cites] Mod Pathol. 2005 Feb;18 Suppl 2:S131-45 [15502808.001]
  • [Cites] J Urol. 1989 Oct;142(4):1003-5 [2677407.001]
  • [Cites] Cancer. 1984 Aug 15;54(4):709-14 [6204734.001]
  • (PMID = 17760973.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2000863
  •  go-up   go-down


27. Ohe C, Kuroda N, Pan CC, Yang XJ, Hes O, Michal M, Uehara H, Hamada S, Kirime S, Senzaki H: A unique renal cell carcinoma with features of papillary renal cell carcinoma and thyroid-like carcinoma: a morphological, immunohistochemical and genetic study. Histopathology; 2010 Sep;57(3):494-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Carcinoma, Renal Cell / genetics. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / genetics. Kidney Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Follicular. Carcinoma / pathology. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Thyroid Neoplasms / genetics. Thyroid Neoplasms / metabolism. Thyroid Neoplasms / pathology


28. Kuroda N, Tamura M, Hes O, Michal M, Kawada C, Shuin T, Lee GH: Renal cell carcinoma with extensive clear cell change sharing characteristics of mucinous tubular and spindle cell carcinoma and papillary renal cell carcinoma. Pathol Int; 2009 Sep;59(9):687-8
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / pathology. Carcinoma / pathology. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Chromosome Aberrations. Chromosomes, Human, Pair 15. Chromosomes, Human, Pair 22. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasms, Multiple Primary. Nephrectomy






Advertisement